Thromb Haemost 2004; 92(01): 171-177
DOI: 10.1160/TH03-11-0707
Cell Signalling and Vessel Remodelling
Schattauer GmbH

Proteasome inhibitor prevents experimental arterial thrombosis in renovascular hypertensive rats

Justyna K. Ostrowska
1   Department of Oncology, Medical University of Bialystok, Poland
,
Marek Z.Wojtukiewicz
1   Department of Oncology, Medical University of Bialystok, Poland
,
Ewa Chabielska
2   Department of Biopharmacy, Medical University of Bialystok, Poland
,
Wlodzimierz Buczko
3   Department of Pharmacodynamics, Medical University of Bialystok, Poland
,
Halina Ostrowska
4   Department of Biology, Medical University of Bialystok, Poland
› Institutsangaben

Financial support: This work was supported by a grant from the Polish Committee for Scientific Research (KBN) 6PO5A 033 20.
Weitere Informationen

Publikationsverlauf

Received 20. November 2003

Accepted after resubmission 02. April 2004

Publikationsdatum:
29. November 2017 (online)

Preview

Summary

Recent studies indicate that highly selective proteasome inhibitors can be useful in prevention of some cardiovascular events. Here we demonstrate that proteasome inhibitor, Z-IleGlu (Ot-Bu) Ala-Leucinal (PSI), is active in the prevention of platelet-dependent arterial thrombosis induced in renovascular hypertensive rats (two-kidney, one clip Goldblatt model, and 2K1C, n=5).The administration of PSI intravenously at a single dose of 0.3 mg/kg before induction of arterial thrombosis markedly increased carotid final flow rate, as compared to control (vehicle) group (10.36 ± 1.8 ml/min and 1.2 ± 1.2 ml/min, respectively), significantly decreased the wet (1.23 ± 0.23 mg and 4.1 ± 0.94 mg, respectively), and dry (0.46 ± 0.145 mg and 1.46 ± 0.39, respectively) thrombus weight, and completely prevented arterial occlusion. Moreover, platelets from PSI treated thrombotic 2K1C rats, showed in response to collagen a significant inhibition of aggregation in the whole blood (10.26 ± 0.6 ohms vs. 15.51 ± 0.91ohms in the control group). In contrast, collagen-induced platelet aggregation was not inhibited in vitro, after pre-treatment of the blood with PSI at the concentration of 10μM that effectively inhibited the 20S proteasome activity in platelets, indicating that ex vivo anti-aggregatory effect of PSI proceeds through an indirect mechanism not associated with suppression of 20S proteasome activity in platelets. In conclusion, our in vivo findings demonstrate that proteasome inhibitor, Z-Ile-Glu(Ot-Bu)Ala-Leucinal, prevents the development of arterial thrombosis in renovascular hypertensive rats and effectively suppresses platelet aggregation by an indirect mechanism. Thus the data provide a new insight into the potential role for the proteasome-dependent pathway in cardiovascular events.